Elevance Looks Cheap Now: But is it Time to Buy or Dodge?

Elevance Health (ELV) is trading at a forward P/E of 10.35x, below its 5-year median and peers like UNH and HUM, driven by growth in its commercial segment, a 9.94% ROIC, and significant share buybacks; however, headwinds include declining Medicaid/Medicare Supplement membership, rising medical costs pushing up the benefit expense ratio, and regulatory uncertainty in the PBM space, resulting in a Zacks Rank #3 (Hold) and a balanced risk-reward profile.

Analysis

Elevance Health (ELV) currently trades at a forward 12-month P/E ratio of 10.35X, a significant discount compared to its five-year median of 13.46X, the industry average of 13.86X, and peers such as UnitedHealth Group (12.06X) and Humana (14.73X), earning it a Zacks Value Score of A. This valuation is supported by robust growth in its commercial segment, with risk-based and fee-based commercial memberships increasing by 4.6% and 1% year-over-year in 2024, respectively, and a notable 14.2% surge in its Individual Commercial business in the first quarter of 2025. The company has strategically streamlined its government business by exiting underperforming markets and possesses opportunities for Medicare Advantage expansion. Elevance demonstrates superior capital efficiency with a Return on Invested Capital of 9.94%, well above the industry's 5.79%, and actively returns capital through share repurchases ($880 million in Q1 2025 with $8.4 billion remaining authorization) and a dividend yield of 1.82%, exceeding the industry average of 1.40%. Year-to-date, ELV shares have gained 1.9%, outperforming the industry and the S&P 500, with consensus EPS estimates projecting 4.2% growth for 2025 and 13.8% for 2026. However, the company faces headwinds, including declining Medicaid and Medicare Supplement memberships, potential pressure from reduced government funding, and rising medical costs, reflected in an increasing benefit expense ratio which rose from 87% in 2023 to 88.5% in 2024 and is estimated to reach 88.7% in 2025. Regulatory uncertainties, particularly concerning its Pharmacy Benefit Management (PBM) operations, also introduce risk, contributing to its Zacks Rank #3 (Hold) status.

Key Decisions for Investors

• Investors may find Elevance Health's current valuation attractive given its strong commercial segment growth, superior capital deployment, and commitment to shareholder returns, warranting consideration for a long-term, value-oriented position.
• It is crucial to monitor the company's benefit expense ratio and membership trends in government programs, as persistent negative developments in these areas could erode profitability and offset commercial segment gains.
• Given the noted headwinds from rising medical costs, potential government funding pressures, and PBM regulatory uncertainty, a cautious approach is advised; while not an immediate strong buy, the stock merits observation for more definitive positive catalysts or resolution of these uncertainties.